文献速递肿瘤 PET/CT

[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT在复发性软组织肉瘤中的头对头评价

Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-02-03

45例软组织肉瘤患者在一周内先后接受[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT检查。共识别282处局部复发和远处转移灶,[68Ga]Ga-DOTA-FAPI-04检出更多病灶(275 vs 186)且诊断灵敏度、特异度、PPV、NPV和准确率均更优(P < 0.001)。在脂肪肉瘤、恶性孤立性纤维性肿瘤和交错树突细胞肉瘤中,[68Ga]Ga-DOTA-FAPI-04的SUVmax和TBR显著更高;而在未分化多形性肉瘤和横纹肌肉瘤中,[18F]FDG的SUVmax和TBR更优。

要点

  • [68Ga]Ga-DOTA-FAPI-04较[18F]FDG检出更多复发转移灶(275 vs 186),诊断效能更优(P < 0.001)。
  • 脂肪肉瘤、恶性孤立性纤维性肿瘤和交错树突细胞肉瘤中,[68Ga]Ga-DOTA-FAPI-04的SUVmax和TBR更高。
  • 未分化多形性肉瘤和横纹肌肉瘤中,[18F]FDG的SUVmax和TBR更优。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT是软组织肉瘤复发监测有前景的新影像方法,在识别脂肪肉瘤、恶性孤立性纤维性肿瘤和交错树突细胞肉瘤的复发灶方面优于[18F]FDG。

研究设计与样本

  • 共纳入45例软组织肉瘤患者(21例女性,24例男性;中位年龄46岁,范围18-71岁),涵盖13种亚型,在1周内分别接受[18F]FDG和[68Ga]Ga-DOTA-FAPI-04 PET/CT检查以评估局部复发或远处转移。
  • PET/CT阳性病灶通过活检或3个月随访验证。
  • 采用Wilcoxon配对符号秩检验比较两种示踪剂在肿瘤病灶中的半定量值(SUVmax和TBR),采用McNemar检验比较两种示踪剂的差异。

主要发现

  • 45例患者共识别282处局部复发和远处转移灶。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT检出275处病灶,[18F]FDG PET/CT检出186处病灶(275 vs 186)。
  • [68Ga]Ga-DOTA-FAPI-04在复发灶诊断的灵敏度、特异度、PPV、NPV和准确率上均优于[18F]FDG(P < 0.001)。
  • 在脂肪肉瘤中,[68Ga]Ga-DOTA-FAPI-04的SUVmax和TBR显著高于[18F]FDG(P = 0.011和P < 0.001)。
  • 在恶性孤立性纤维性肿瘤和交错树突细胞肉瘤中,[68Ga]Ga-DOTA-FAPI-04的SUVmax和TBR均显著高于[18F]FDG(P < 0.001和P < 0.001)。

关键数值与推荐

  • 在未分化多形性肉瘤中,[18F]FDG的平均SUVmax和TBR优于[68Ga]Ga-DOTA-FAPI-04(P = 0.003和P < 0.001)。
  • 在横纹肌肉瘤中,[18F]FDG的平均SUVmax和TBR优于[68Ga]Ga-DOTA-FAPI-04(P < 0.001和P < 0.001)。

临床怎么用

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT在软组织肉瘤复发监测中显示出优于[18F]FDG的诊断效能,尤其在脂肪肉瘤、恶性孤立性纤维性肿瘤和交错树突细胞肉瘤中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate the value of [68 Ga]Ga-DOTA-FAPI-04 PET/CT for the diagnosis of recurrent soft tissue sarcoma (STS), compared with [18F]FDG PET/CT. METHODS: A total of 45 patients (21 females and 24 males; median age, 46 years; range, 18-71 years) with 13 subtypes of STS underwent [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT examination within 1 week for assessment local relapse or distant metastasis. Positive lesions on PET/CT images were verified by biopsy or 3-month follow-up. Wilcoxon matched-pairs signed-rank test was used to compare the semiquantitative values (SUVmax and TBR) of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 in tumor lesions, and McNemar test was applied to test for differences of both tracers. RESULTS: Among the 45 patients, 282 local relapses and distant metastases were identified. Compared to [18F]FDG, [68 Ga]Ga-DOTA-FAPI-04 PET/CT detected more lesions (275 vs. 186) and outperformed in sensitivity, specificity, PPV, NPV, and accuracy for the diagnosis of recurrent lesions (P < 0.001). [68 Ga]Ga-DOTA-FAPI-04 demonstrated significantly higher values of SUVmax and TBR than [18F]FDG PET/CT in liposarcoma (P = 0.011 and P < 0.001, respectively), malignant solitary fibrous tumor (MSFT) (P < 0.001 and P < 0.001, respectively), and interdigitating dendritic cell sarcoma (IDCS) (P < 0.001and P < 0.001, respectively). While mean SUVmax and TBR presented favorable uptake of [18F]FDG over [68 Ga]Ga-DOTA-FAPI-04 in undifferentiated pleomorphic sarcoma (UPS) (P = 0.003 and P < 0.001, respectively) and rhabdomyosarcoma (RMS) (P < 0.001 and P < 0.001, respectively). CONCLUSION: [68 Ga]Ga-DOTA-FAPI-04 PET/CT is a promising new imaging modality for recurrent surveillance of STS, and compares favorably with [18F]FDG for identifying recurrent lesions of liposarcoma, MSFT, and IDCS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gu B, Liu X, Wang S, et al. Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35113192. doi:10.1007/s00259-022-05700-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。